-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 28, Qilu Pharmaceutical issued a press release stating that the listing application of its Class 1 new drug Yiluok tablets has been accepted by the National Food and Drug Administration (NMPA) of China
According to the press release, WX-0593 can inhibit the activity of different fusion types of wild-type and ALK inhibitor-resistant mutations of ALK kinase, and can effectively inhibit the activity of different fusion types of ROS1 kinase
In May 2016, WX-0593 was applied for clinical application in China for the first time
At the European Society of Medical Oncology (ESMO) conference in 2019, Qilu Pharmaceutical announced the Phase 1 clinical data of WX-0593
This result shows the therapeutic advantages of WX-0593 tablets with low starting dose, rapid onset of action, and wide safety window.
